Focus: Zevra Therapeutics is a Denmark-based biotech company focused on rare disease treatment through modifications of existing drugs. The company operates at mid-cap biotech scale with a marketed product and a growing clinical pipeline.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Best suited for Medical Affairs or regulatory professionals seeking rare disease expertise and commercial-stage stability; risky for R&D-focused careers due to limited pipeline depth and opaque finances.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Company's sole marketed revenue generator; faces patent cliff in 2031 requiring pipeline maturation within 7 years.
Help build intelligence for Zevra Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Zevra Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Zevra Therapeutics rises amid takeover speculation - MSN
Zevra Therapeutics rises amid takeover speculation MSN
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) ChartMill
Zevra Therapeutics rises amid takeover speculation - MSN
Zevra Therapeutics rises amid takeover speculation MSN
Zevra to release first-quarter results after market close May 6 - Stock Titan
Zevra to release first-quarter results after market close May 6 Stock Titan
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call - Yahoo Finance
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call Yahoo Finance
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call - Sahm
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call Sahm
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trial.
Efficacy results from a 12-month double-blind randomized trial of arimoclomol for treatment of Niemann-Pick disease type C (NPC): Presenting a rescored 4-domain NPC Clinical Severity Scale.
Showing 5 of 6 publications